DarioHealth (DarioHealth) Change In Working Capital : $4.07 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is DarioHealth Change In Working Capital?

DarioHealth's change in working capital for the quarter that ended in Dec. 2023 was $2.21 Mil.

DarioHealth's change in working capital for the fiscal year that ended in Dec. 2023 was $4.07 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

DarioHealth Change In Working Capital Historical Data

The historical data trend for DarioHealth's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DarioHealth Change In Working Capital Chart

DarioHealth Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-0.43

0.42

-2.57

-10.90

4.07

DarioHealth Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-1.45	2.31	-1.37	0.93	2.21

DarioHealth Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.07 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

DarioHealth Change In Working Capital Related Terms

Thank you for viewing the detailed overview of DarioHealth's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

DarioHealth (DarioHealth) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DarioHealth Corp (NAS:DRIO) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 W. 18th Street, New York, NY, USA, 10011

Website

https://www.mydario.com

DarioHealth Corp is a digital health company. It offers user-centric a multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally.

Executives

Jon H. Kaplan	director	1573 MALLORY LANE, SUITE 100, BRENTWOOD TN 37027
Erez Raphael	director, officer: Chief Executive Officer	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Dennis M Mcgrath	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Dror Bacher	officer: Chief Operating Officer	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK L3 3088900
Oded Cohen	officer: GM MSK	8 HATOKHEN ST., CAESAREA INDUSTRIAL PARK L3 3088900
Adam K Stern	director	STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Dennis Matheis	director	8 HATOKHEN ST., CAESAREA L3 38900
Yoav Shaked	director	8 HATOKHEN ST., CAESAREA L3 3088900
Yadin Shemmer	director	8 HATOKHEN ST., CAESAREA L3 3088900
Richard Allan Anderson	officer: President, GM of North America	C/O DARIOHEALTH CORP., 18 W. 18TH ST, 5TH FLOOR, NEW YORK NY 10011
Yalon Farhi	director	C/O LABSTYLE INNOVATIONS CORP., 9 HALAMISH ST., CAESAREA INDUSTRIAL PARK, CAESAREA L3 3088900
Hila Karah	director	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Zvi Ben-david	officer: Chief Financial Officer	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Glen Moller	director	8 HATOKHEN ST., CAESAREA L3 3088900
Olivier Roger Jarry	officer: See Remarks	15 ROCKRIDGE RD, LARCHMONT NY 10538-3918